Efgartigimod - A Novel Treatment for Myasthenia Gravis
Efgartigimod is a neonatal Fc receptor blocker used to treat myasthenia gravis by targeting and neutralizing immune components that contribute to the condition.
Efgartigimod alfa and Hyaluronidase-qvfc - An Overview
Efgartigimod alfa and Hyaluronidase-qvfc treat gMG and CIDP in adults, enhancing muscle strength and slowing symptom progression.
